The product information provided in this site is intended for residents of the United States.

Clinical Case Studies Series

Patients With Chronic Diarrhea and Loose Stools

IBS

1. A Clinical Series: IBS Patients

IBS-Patients

Case series of 10 drug-refractory IBS patients who respond to oral serum-derived bovine immunoglobulin/protein isolate (SBI)

Hilal R, Mitchell P, Guerra E Jr, Burnett B.

To view the full article: www.HilalIBSDReprint.com

2. A Clinical Series: IBS-D/IBS-M Patients

IBS-D_IBS-M_Patients

Serum-derived bovine immunoglobulin/protein isolate therapy for patients with refractory irritable bowel syndrome

Weinstock LB, Jasion VS.

To view the full article: www.WeinstockIBSDReprint.com

3. A Clinical Series: IBS-D/IBS-U/IBS-M/IBS-C Patients

IBS-D_IBS-U_IBS-M_IBS-C_Patients

New therapeutic option for irritable bowel syndrome: Serum-derived bovine immunoglobulin

Good L, Rosario R, Panas R.

To view the full article: www.GoodIBSDReprint.com

4. A Clinical Series: Post-infectious IBS-D Patients

Post-infectious_IBS-D_Patients

Post-infectious irritable bowel syndrome with functional diarrhea following C. difficile infections: Case studies of responses using serum-derived bovine immunoglobulin

Crawford CV, Panas RM.

To view the full article: www.CrawfordIBSDReprint.com

IBD

5. A Clinical Series: IBD Patients
 

IBD_Patients

Case series investigating the clinical practice experience of serum-derived bovine immunoglobulin/ protein isolate (SBI) in the clinical management of patients with inflammatory bowel disease

Good L, Panas R.

To view the full article: www.GoodIBDReprint.com

6. A Clinical Series: Patient With Refractory Ulcerative Colitis (UC)

Patient_With_Refractory_Ulcerative_Colitis

Successful management of refractory ulcerative colitis with orally administered serum-derived bovine immunoglobulin therapy

Beauerle BD, Burnett BP, Dryden GW.

To view the full article: www.DrydenIBDReprint.com

7. Retrospective Case Series: IBD Patients

Retrospective_IBD_Patients

Management of inflammatory bowel disease with oral serum-derived bovine immunoglobulin

Shafran I, Burgunder P, Wei D, Young HE, Klein G, Burnett BP.

To view the full article: www.ShafranIBDReprint.com

8. Case Series: Chronic Colitis Patients

Chronic_Colitis_Patients

Use of a nutritional therapy, serum-derived bovine immunoglobulin/protein isolate (SBI), to achieve improvement in two different cases of colitis

Awad A, Jasion VS.

To view the full article: www.AwadColitisReprint.com

Intended Use

EnteraGam® is a medical food product intended for the dietary management of chronic diarrhea and loose stools. EnteraGam® must be administered under medical supervision.

Important Safety Information:

EnteraGam® contains beef protein: therefore, patients who have an allergy to beef or any other component of EnteraGam® should not take this product. EnteraGam® has not been studied in pregnant women, in women during labor and delivery, or in nursing mothers. The choice to administer EnteraGam® during pregnancy, labor and delivery, or to nursing mothers is at the clinical discretion of the prescribing physician.

EnteraGam® does not contain any milk-derived ingredients such as lactose, casein, or whey. EnteraGam® is gluten-free, dye-free, and soy-free.

Please see full Product Information

To report suspected adverse reactions, contact Entera Health, Inc. at 1-855-4ENTERA (1-855-436-8372), or the FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch.